Nasal Delivery of CNS Therapeutics (R43/R44)
The summary for the Nasal Delivery of CNS Therapeutics (R43/R44) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Nasal Delivery of CNS Therapeutics (R43/R44): The purpose of this Small Business Technology Transfer (STTR) RFA is to develop a nasal delivery formulation that reliably delivers of a therapeutic (e.g., peptides, antibodies, RNAi, or pharmacotherapeutics), at a physiologically relevant concentration, into the central nervous system (CNS).
Federal Grant Title: | Nasal Delivery of CNS Therapeutics (R43/R44) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DA-18-006 |
Type of Funding: | Grant |
CFDA Numbers: | 93.279 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | August 23rd, 2017 |
Original Application Deadline: | August 23rd, 2017 |
Posted Date: | April 25th, 2017 |
Creation Date: | April 25th, 2017 |
Archive Date: | September 28th, 2017 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | April 25th, 2017 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See Funding Opportunity for eligibility details
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-18-006.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
- • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
- • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...
- • Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - C...
- • Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trials Not ...
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)